Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation.
- The company maintains royalty participation and equity ownership exposure to unbuzzd(TM) while preserving pharmaceutical and medical-use rights to related formulations.
- Lucid-MS has completed Phase 1 safety studies and advanced into the IND submission stage ahead of a planned Phase 2 clinical trial in multiple sclerosis.
- Quantum BioPharma’s portfolio spans both therapeutic drug development and consumer-focused wellness products, creating multiple potential operational and commercialization pathways.
- The company has reported sufficient working capital to sustain basic operations beyond January 2028 while continuing development across its pipeline and strategic initiatives.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company is advancing a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need.
The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.
The company is headquartered in Toronto, Ontario.
Portfolio
Lucid-MS
Lucid-MS (Lucid-21-302) is a patented new chemical entity being developed as a potential treatment for multiple sclerosis and other demyelinating diseases. The compound has demonstrated in preclinical models the ability to prevent and reverse myelin degradation while preserving neuronal health. According to the company, Lucid-MS is designed as a non-immunomodulatory, neuroprotective therapy targeting demyelination, a key driver of disease progression in multiple sclerosis.
Quantum BioPharma completed Phase 1 Single Ascending Dose (“SAD”) and Multiple Ascending Dose (“MAD”) studies evaluating the safety and tolerability of Lucid-MS in healthy volunteers. The company submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration in March 2026 to support a planned Phase 2 clinical trial in multiple sclerosis patients. The focus of the study is intended to be in patients suffering from PPMS (primary progressive) and SPMS (secondary progressive) types of the disease. Quantum BioPharma has also entered into a binding letter of intent with global clinical research organization Allucent to support the planned Phase 2 study.
Lucid-MS has been studied through more than a decade of research and development and has shown efficacy in several preclinical animal models. Quantum BioPharma maintains exclusive worldwide rights to the compound through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
unbuzzd(TM) and REKVRY(TM)
Quantum BioPharma developed unbuzzd(TM), a dietary supplement beverage formulation designed to accelerate alcohol metabolism, reduce blood alcohol concentration and improve mental alertness following alcohol consumption. The company spun out the over-the-counter consumer version of the product to Unbuzzd Wellness Inc., formerly Celly Nutrition Corp., while retaining an ownership stake and royalty participation. Under the agreement, Quantum BioPharma retains a 7% royalty on sales of unbuzzd(TM) until aggregate payments reach $250 million, after which the royalty decreases to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
In March 2026, results from a double-blind, randomized, placebo-controlled crossover clinical trial investigating unbuzzd(TM) were published in a peer-reviewed scientific journal. According to the company, the study demonstrated statistically significant improvements in alcohol metabolism, reductions in blood alcohol concentration, improved alertness and reduced hangover symptoms compared to placebo.
Quantum BioPharma is also developing REKVRY(TM), a formulation intended for alcohol misuse treatment in hospital and emergency settings, which the company believes may help address healthcare burden associated with alcohol intoxication and misuse.
Market Opportunity
Quantum BioPharma is targeting large global markets across multiple sclerosis treatment, alcohol recovery products and functional wellness beverages. According to company materials, approximately 2.8 million people worldwide are living with multiple sclerosis, including nearly one million people in the United States alone. The company has cited projections indicating the global multiple sclerosis market could grow from approximately $28.2 billion in 2022 to approximately $41 billion by 2033.
The company is also targeting the growing hangover recovery and alcohol wellness market through unbuzzd(TM). According to Quantum BioPharma’s materials, the global hangover cure products market was valued at approximately $2.05 billion in 2022 and is projected to reach approximately $6.2 billion by 2030, representing a compound annual growth rate of 14.8%. Quantum BioPharma has additionally cited estimates that excessive alcohol consumption costs the United States approximately $249 billion annually through healthcare costs, lost productivity, criminal justice impacts, vehicle crashes and property damage. The company has also referenced projections estimating the broader functional beverage market could reach approximately $198 billion in 2026.
Leadership Team
Zeeshan Saeed, Founder, CEO, President & Executive Co-Chair, founded Quantum BioPharma and played a key role in securing the company’s initial seed capital and transition into a publicly traded company. Prior to founding Quantum BioPharma, he served as President of ZZ Telecommunications Inc., a long-distance telecommunications carrier, and previously founded Platinum Telecommunications Inc. Mr. Saeed has experience in international capital markets, including assisting startups with raising capital and securing exchange listings, and holds a Bachelor of Science in Mechanical Engineering.
Anthony Durkacz, Co-Founder & Executive Co-Chair and previously served as President of Capital Ideas Investor Relations, was the CFO and a director of Snipp Interactive, as well as was COO and CFO of MKU Canada and Astris Energi.
Donal Carroll, CPA, CFO & COO, has more than 20 years of corporate finance leadership and public company experience. Prior to joining Quantum BioPharma, he served as Country CFO with Videojet Technologies, a Danaher company, Accounting Supervisor with Alberto Culver, now part of Unilever, and Corporate Controller with Cardinal Meats.
Jason Sawyer, Head of Finance and M&A, is a veteran financier who has led Bahamas-based alternative investment and advisory firm Access Alternative Group S.A. for more than 20 years. According to the company, AAG and its affiliates have completed more than $5 billion in capital placements involving alternative fund managers, private and public startups, early-stage growth companies and targeted mergers and acquisitions across multiple sectors. Mr. Sawyer also serves on various corporate boards and advisory committees.
Lakshmi P. Kotra, PhD, President of Quantum BioPharma and CEO of Quantum BioPharma Australia Pty Ltd., is a Senior Scientist at the Krembil Brain Institute within University Health Network and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra joined Quantum BioPharma in connection with the acquisition of Lucid Psycheceuticals in 2021 and is the recipient of the Julia Levy Award for contributions to the commercialization of biomedical innovation in Canada. His background includes research and development work involving anti-HIV drugs, antibacterials, insulin, antimalarials, medical cannabis therapeutics and treatments targeting multiple sclerosis.
Andrzej Chruscinski, MD, PhD, Vice-President, Clinical and Scientific Affairs, leads Quantum BioPharma’s clinical programs and clinical trial activities. Dr. Chruscinski received his MD and PhD from Stanford University, completed residency training in internal medicine at Stanford and fellowships in cardiology at Stanford and Toronto General Hospital. He has led major clinical trials involving transplantation tolerance and biomarker discovery and is a board-certified cardiologist.
Eric Hoskins, MD, DPhil, Director, is a physician and public health expert with more than 30 years of experience spanning healthcare, public policy, economic development and international trade. Dr. Hoskins previously served as Ontario’s Minister of Health and Long-Term Care and held several additional cabinet positions during nearly a decade as a member of provincial parliament. He also served as president of War Child Canada and was awarded the Order of Canada in 2007 for his humanitarian work.
For more information, visit the company’s website at www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation.
- The company maintains royalty participation and equity ownership exposure to unbuzzd(TM) while preserving pharmaceutical and medical-use rights to related formulations.
- Lucid-MS has completed Phase 1 safety studies and advanced into the IND submission stage ahead of a planned Phase 2 clinical trial in multiple sclerosis.
- Quantum BioPharma’s portfolio spans both therapeutic drug development and consumer-focused wellness products, creating multiple potential operational and commercialization pathways.
- The company has reported sufficient working capital to sustain basic operations beyond January 2028 while continuing development across its pipeline and strategic initiatives.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company is advancing a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need.
The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.
The company is headquartered in Toronto, Ontario.
Portfolio
Lucid-MS
Lucid-MS (Lucid-21-302) is a patented new chemical entity being developed as a potential treatment for multiple sclerosis and other demyelinating diseases. The compound has demonstrated in preclinical models the ability to prevent and reverse myelin degradation while preserving neuronal health. According to the company, Lucid-MS is designed as a non-immunomodulatory, neuroprotective therapy targeting demyelination, a key driver of disease progression in multiple sclerosis.
Quantum BioPharma completed Phase 1 Single Ascending Dose (“SAD”) and Multiple Ascending Dose (“MAD”) studies evaluating the safety and tolerability of Lucid-MS in healthy volunteers. The company submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration in March 2026 to support a planned Phase 2 clinical trial in multiple sclerosis patients. The focus of the study is intended to be in patients suffering from PPMS (primary progressive) and SPMS (secondary progressive) types of the disease. Quantum BioPharma has also entered into a binding letter of intent with global clinical research organization Allucent to support the planned Phase 2 study.
Lucid-MS has been studied through more than a decade of research and development and has shown efficacy in several preclinical animal models. Quantum BioPharma maintains exclusive worldwide rights to the compound through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
unbuzzd(TM) and REKVRY(TM)
Quantum BioPharma developed unbuzzd(TM), a dietary supplement beverage formulation designed to accelerate alcohol metabolism, reduce blood alcohol concentration and improve mental alertness following alcohol consumption. The company spun out the over-the-counter consumer version of the product to Unbuzzd Wellness Inc., formerly Celly Nutrition Corp., while retaining an ownership stake and royalty participation. Under the agreement, Quantum BioPharma retains a 7% royalty on sales of unbuzzd(TM) until aggregate payments reach $250 million, after which the royalty decreases to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
In March 2026, results from a double-blind, randomized, placebo-controlled crossover clinical trial investigating unbuzzd(TM) were published in a peer-reviewed scientific journal. According to the company, the study demonstrated statistically significant improvements in alcohol metabolism, reductions in blood alcohol concentration, improved alertness and reduced hangover symptoms compared to placebo.
Quantum BioPharma is also developing REKVRY(TM), a formulation intended for alcohol misuse treatment in hospital and emergency settings, which the company believes may help address healthcare burden associated with alcohol intoxication and misuse.
Market Opportunity
Quantum BioPharma is targeting large global markets across multiple sclerosis treatment, alcohol recovery products and functional wellness beverages. According to company materials, approximately 2.8 million people worldwide are living with multiple sclerosis, including nearly one million people in the United States alone. The company has cited projections indicating the global multiple sclerosis market could grow from approximately $28.2 billion in 2022 to approximately $41 billion by 2033.
The company is also targeting the growing hangover recovery and alcohol wellness market through unbuzzd(TM). According to Quantum BioPharma’s materials, the global hangover cure products market was valued at approximately $2.05 billion in 2022 and is projected to reach approximately $6.2 billion by 2030, representing a compound annual growth rate of 14.8%. Quantum BioPharma has additionally cited estimates that excessive alcohol consumption costs the United States approximately $249 billion annually through healthcare costs, lost productivity, criminal justice impacts, vehicle crashes and property damage. The company has also referenced projections estimating the broader functional beverage market could reach approximately $198 billion in 2026.
Leadership Team
Zeeshan Saeed, Founder, CEO, President & Executive Co-Chair, founded Quantum BioPharma and played a key role in securing the company’s initial seed capital and transition into a publicly traded company. Prior to founding Quantum BioPharma, he served as President of ZZ Telecommunications Inc., a long-distance telecommunications carrier, and previously founded Platinum Telecommunications Inc. Mr. Saeed has experience in international capital markets, including assisting startups with raising capital and securing exchange listings, and holds a Bachelor of Science in Mechanical Engineering.
Anthony Durkacz, Co-Founder & Executive Co-Chair and previously served as President of Capital Ideas Investor Relations, was the CFO and a director of Snipp Interactive, as well as was COO and CFO of MKU Canada and Astris Energi.
Donal Carroll, CPA, CFO & COO, has more than 20 years of corporate finance leadership and public company experience. Prior to joining Quantum BioPharma, he served as Country CFO with Videojet Technologies, a Danaher company, Accounting Supervisor with Alberto Culver, now part of Unilever, and Corporate Controller with Cardinal Meats.
Jason Sawyer, Head of Finance and M&A, is a veteran financier who has led Bahamas-based alternative investment and advisory firm Access Alternative Group S.A. for more than 20 years. According to the company, AAG and its affiliates have completed more than $5 billion in capital placements involving alternative fund managers, private and public startups, early-stage growth companies and targeted mergers and acquisitions across multiple sectors. Mr. Sawyer also serves on various corporate boards and advisory committees.
Lakshmi P. Kotra, PhD, President of Quantum BioPharma and CEO of Quantum BioPharma Australia Pty Ltd., is a Senior Scientist at the Krembil Brain Institute within University Health Network and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra joined Quantum BioPharma in connection with the acquisition of Lucid Psycheceuticals in 2021 and is the recipient of the Julia Levy Award for contributions to the commercialization of biomedical innovation in Canada. His background includes research and development work involving anti-HIV drugs, antibacterials, insulin, antimalarials, medical cannabis therapeutics and treatments targeting multiple sclerosis.
Andrzej Chruscinski, MD, PhD, Vice-President, Clinical and Scientific Affairs, leads Quantum BioPharma’s clinical programs and clinical trial activities. Dr. Chruscinski received his MD and PhD from Stanford University, completed residency training in internal medicine at Stanford and fellowships in cardiology at Stanford and Toronto General Hospital. He has led major clinical trials involving transplantation tolerance and biomarker discovery and is a board-certified cardiologist.
Eric Hoskins, MD, DPhil, Director, is a physician and public health expert with more than 30 years of experience spanning healthcare, public policy, economic development and international trade. Dr. Hoskins previously served as Ontario’s Minister of Health and Long-Term Care and held several additional cabinet positions during nearly a decade as a member of provincial parliament. He also served as president of War Child Canada and was awarded the Order of Canada in 2007 for his humanitarian work.
For more information, visit the company’s website at www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
